About US
Contact us
-
Merck's Keytruda thumped SeaGen's Adcetris in a head-to-head trial. How much does it matter?Merck’s Keytruda has taken on the standard of care in classical Hodgkin lymphoma and won. But with a closely watched combination making its way through the clinic,how long will the results be relevan2020/5/6
-
AstraZeneca, with a heavy focus on China, sees key meds outperform despite COVID-19When the novel coronavirus was first identified in China and put the entire country on high alert, there were concerns that the outbreak would hit AstraZeneca hard, given its high exposure to the eme2020/4/30
-
Merck grabs FDA green light for less-frequent Keytruda dosing regimenThat didn’t take long. Just days after resubmitting its application to the FDA, Merck nabbed an approval Tuesday for a new, more convenientKeytruda dosing regimen The FDAgreen lightclearedthe immuno-2020/4/30
-
Merck, with a heavy presence in physician-administered drugs, predicts a $2.1B sales hit from COVID-19Whiledrugmakersacross the industry deal withtheir respectiveCOVID-19challenges, Merck faces a unique set of circumstances because of its reliance on physician-administered drugs. Several companies ha2020/4/29
-
Novartis, already trialing hydroxychloroquine and Jakafi, plans COVID-19 testing for IlarisAnother existing drug is being pitted against COVID-19. This time, it’s Novartis’ immunology med Illaris. On Monday, Novartis said itplannedto studyIlaris (canakinumab) in a phase 3 trial to see if t2020/4/28
-
Gilead ratchets up its Truvada patent fight with U.S. in new breach-of-contract lawsuitGilead Sciences and federal authorities have been locked in a high-stakes fight over patents on an HIV prevention drug, and now Gilead has filed the latest salvo. In a new lawsuit, the Big Biotech cl2020/4/28
-
Bayer business up in the air as COVID-19 and Roundup litigation uncertainties persistLike several other pharma companies, Bayer enjoyed a better-than-expected first quarter in the early days of COVID-19. But the German conglomerate finds the uncertainties spawned by the pandemic make2020/4/27
-
After disappointing early numbers, Sanofi and Regeneron scale back Kevzara's COVID-19 testSanofi and Regeneron had high hopes for IL-6 inhibitor Kevzara's chances as a repurposed therapy for COVID-19 patients after anecdotal results in China showed promise. But now, the drug has hit an ea2020/4/27
-
J&J, AbbVie's Imbruvica pads CLL lead with FDA green light in younger patientsMany chronic lymphocytic leukemia (CLL) patients start out on Johnson & Johnson and AbbVie’s Imbruvica, a blockbuster that until recently had five indications in the disease. Thanks to a sixthgra2020/4/23
-
Early treatment with Novartis' Mayzent stalls secondary progressive MS: studyNovartis is looking to grow its new multiple sclerosis drug Mayzent in a crowded field, and, with Gilenya generics threatening, the newer MS medicine may need to carry even more weight. It just racke2020/4/22